期刊文献+

肺腺癌胸苷酸合成酶表达与放射敏感性的关系 被引量:1

The relationship between thymidylate synthase expression and radiosensitivity of lung adenocarcinoma
下载PDF
导出
摘要 目的:探讨肺腺癌患者胸苷酸合成酶(TS)不同表达水平与放射敏感性的关系。方法:对经病理确诊的94例局部晚期肺腺癌患者,根据TS不同表达水平,将患者分为高表达组(40例)和低表达组(54例)。对患者的肺部原发病灶行体部伽玛刀立体定向适形放射治疗,放疗结束后1个月复查胸部CT评价近期疗效。结果:全部患者均按计划完成治疗,两组近期疗效:高表达组:CR 3例,PR 27例,SD 7例,PD 3例,近期总有效率为75.0%[(CR+PR)/总病例数×100%];低表达组:CR 8例,PR 41例,SD 3例,PD 2例,近期总有效率为90.7%。两组近期疗效比较差异有统计学意义(P<0.05)。结论:肺腺癌TS低表达组的放疗后近期疗效好,提示TS表达水平可能作为肺腺癌放射敏感性的标志物之一。 Objective: To investigate the relationship between the levels of thymidylate synthetase( TS) and radiosensitivity in patients with lung adenocarcinoma.Methods: Atotal of 94 patients with locally advanced lung adenocarcinoma confirmed by pathology were divided into high expression group( 40 cases) and low expression group( 54 cases) according to the different expression level of TS.The patients' primary lung lesions were treated with body gamma knife stereotactic radiotherapy,and 1 months after the end of the radiotherapy,the immediate effect of the chest CT was reviewed.Results: All the patients completed the treatment according to the plan.The short-term efficacy of the two groups were as follows: In high expression group with CR 3 cases,PR 27 cases,SD 7 cases and PD 3 cases,the total effective rate was 75.0% [( CR + PR)/total cases × 100%].In low expression group with CR 8 cases,PR 41 cases,SD 3 cases,and PD 2 cases,the recent total effective rate was 90.7%.There was a significant difference in the recent curative effect between the two groups( P 0.05).Conclusion: The short term radiotherapy effect of TS low expression group of lung adenocarcinoma is good,suggesting that the expression level of TS may be one of the markers of radiosensitivity of lung adenocarcinoma.
作者 苏琳 苏加利 蔡薇薇 Su Lin;Su Jiali;Cai Weiwei(Department of Oncology,Central South University Xiangya Hospital,Hunan Changsha 410008,China;Department of Oncology,The Second Affiliated Hospital of Hunan Normal University,No.163 Hospital of PLA,Hunan Changsha 410003,China.)
出处 《现代肿瘤医学》 CAS 2018年第18期2863-2866,共4页 Journal of Modern Oncology
基金 湖南省卫生计生委科研计划课题项目(编号:C2016095)
关键词 肺肿瘤 腺癌 胸苷酸合成酶 立体定向适形放疗 体部伽玛刀 放射敏感性 lung neoplasms adenoeareinoma thymidylate synthetase stereotaetie conformal radiotherapy body gamma - knife radiosensitivity
  • 相关文献

参考文献4

二级参考文献31

  • 1Cancer Genome Atlas Research Network. Comprehensive ge- nomic characterization of squamous cell lung cancers[J]. Nature,2012,489 (7 417 ) :519 - 525.
  • 2A1-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in ad- vanced non-small-cell lung cancer : meta-analysis of random- ized controlled trials, with histology subgroup analysis [ J ]. Curr Oncol,2012,19 ( 1 ) : e9 - el5.
  • 3Pallis AG, Georgoulias V. Is there a standard regimen for first-line treatment of advanced/metastatic non-small-ceil lung cancer? What has meta-analyses contributed to today's standard of care [ J 1. Lung Cancer,2012,75 (3) :269 - 274.
  • 4Yoshioka H, Okamoto I, Morita S, et al. Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with ad- vanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study [ J ]. Ann Oncol, 2013,24(5) :1 326- 1 331.
  • 5Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance ther- apy with pemetrexed plus best supportive care versus place- bo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non- small-cell lung cancer ( PARAMOUNT ) : a double-blind, phase 3, randomised controlled trial [ J ]. Lancet Oncol, 2012,13 (3) :247 - 255.
  • 6Nishino M, Cryer SK, Okajima Y, et al. Tumoral cavitation in patients with non-small-cell lung cancer treated with antian- giogenic therapy using bevacizumab [ J ]. Cancer Imaging, 2012,12 ( 1 ) :225 - 235.
  • 7Belani CP, Wu YL, Chen YM, et al. Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non- small cell lung cancer : an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial [J]. J Thorac On- col,2012,7(3) :567 -573.
  • 8Dansin E, Cinieri S, Garrido P, et al. MO19390 (SAIL) : bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC [ J]. Lung Cancer,2012,76 (3) :373 - 379.
  • 9Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer [ J ]. J Clin Oncol, 2012,30(4) :433 -440.
  • 10Schnabel PA, Smit E, Carpefio Jde C, et al. Influence of his- tology and biomarkers on first-line treatment of advanced non- small cell lung cancer in routine care setting:baseline results of an observational study (FRAME) [ J ]. Lung Cancer, 2012, 78(3) :263 -269.

共引文献9

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部